US 12,258,304 B2
Compounds and methods for treatment of bacterial infections
Steven C. Almo, Pelham, NY (US); Tyler Grove, Bronx, NY (US); Lawrence D. Harris, Lower Hutt (NZ); and Gary B. Evans, Lower Hutt (NZ)
Assigned to Albert Einstein College of Medicine, Bronx, NY (US); and Victoria Link Limited, Wellington (NZ)
Appl. No. 17/612,647
Filed by Albert Einstein College of Medicine, Bronx, NY (US); and Victoria Link Limited, Wellington (NZ)
PCT Filed May 20, 2020, PCT No. PCT/US2020/033756
§ 371(c)(1), (2) Date Nov. 19, 2021,
PCT Pub. No. WO2020/236907, PCT Pub. Date Nov. 26, 2020.
Claims priority of provisional application 62/850,245, filed on May 20, 2019.
Prior Publication US 2022/0234995 A1, Jul. 28, 2022
Int. Cl. C07C 229/38 (2006.01); A61P 31/04 (2006.01); C07C 63/14 (2006.01); C07C 323/62 (2006.01); C07D 213/79 (2006.01)
CPC C07C 229/38 (2013.01) [A61P 31/04 (2018.01); C07C 63/14 (2013.01); C07C 323/62 (2013.01); C07D 213/79 (2013.01)] 20 Claims
 
1. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is represented by Formula I,

OG Complex Work Unit Chemistry
wherein:
R1 in each instance independently is hydrogen or C1-10alkyl, wherein the C1-10alkyl is optionally substituted with one or more selected from the group consisting of a halogen, oxo (═O), OH, OC1-4alkyl, SC1-4alkyl, and arylC1-6alkyl;
R2, R3, R4, and R5 are each independently selected from the group consisting of hydrogen, fluorine, chlorine, bromine, C1-4alkyl, CN, C1-6alkylCONH, C1-6alkylNHCO, C1-6alkylSO2NH, C1-6alkylNHSO2, and C1-6alkylSO2;
X is O, S, NH or CH2;
and
Z in each instance independently is C or N, provided that:
when a Z is N, the substituent R2, R3, R4, or R5 attached thereto is void; and
when each Z is C, at least one of R2, R3, R4, and R5 is chlorine or fluorine.